LOS ANGELES, CA - HeartBeam (NASDAQ: BEAT) has launched a new pilot study to evaluate its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia, a condition characterized by inadequate blood flow and oxygen supply to tissue. The study marks a significant step in the development of the HeartBeam patch, which aims to address limitations of current patch-based ambulatory monitors that cannot detect ischemia or provide clinical-grade insights over extended periods.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, the HeartBeam patch could offer a solution. The device is designed to generate an on-demand 12-lead ECG, a diagnostic tool typically available only in clinical settings.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand…” The full statement is available in the company’s newsroom at https://ibn.fm/BEAT.
The pilot study represents a critical step toward validating the technology’s ability to detect ischemia, which could significantly improve early diagnosis and treatment of coronary artery disease. According to the company, the HeartBeam patch has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Forward-looking statements in this article involve risks and uncertainties, including those set forth under "Risk Factors" in HeartBeam’s SEC filings. The original release is available at www.newmediawire.com.
